Uncategorized

Sacrifices and Small Wins: The Fight Against Rising Gun Violence

As gun violence continues to soar in U.S. cities, one violence prevention specialist tries to stem the tide of homicides in his hometown.

Read More

One Woman’s Year Surviving the Pandemic with a Disability

A young woman living with cerebral palsy shares the struggles, fears and silver linings she’s experienced during the pandemic.

Read More

Why Millions Could Lose Medicaid Next Year

A congressional ban on removing anyone from Medicaid is likely to expire early next year.

Read More

One County’s 20-Year Effort to Decriminalize Mental Illness

Miami-Dade County has spent the last two decades trying to connect people in mental distress with services instead of jail cells. What have they learned?

Read More

The Aducanumab Aftermath: The Industry

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?

Read More

The Aducanumab Aftermath: The Payer

A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

Read More

The Aducanumab Aftermath: The Patient

One patient shares her hopes and concerns about a costly new Alzheimer’s drug.

Read More

The Aducanumab Aftermath

The Aducanumab Aftermath A SPECIAL CONVERSATION SERIES June 22, 2021 Art by Leslie Walker About this Special Series The U.S. Food and Drug Administration (FDA) recently approved the costly new Alzheimer’s drug aducanumab (now known by the brand name Aduhelm) despite doubts about its safety and efficacy. Priced at $56,000 by drugmaker Biogen, aducanumab could…

Read More

The Aducanumab Aftermath: The Doctor

One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.

Read More

Babies, Boats & Abstracts: An Insider’s Guide to Health Policy Conferences

Health economist Kosali Simon shares conference tips, stories and abstracts she’s excited for at AcademyHealth and ASHEcon.

Read More